Drug Profile

ROC 101

Alternative Names: ROC-101

Latest Information Update: 17 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sanofi
Developer AllRock Bio
Class Anti-inflammatories; Antifibrotics; Antihypertensives; Small molecules
Mechanism of Action Rho-associated kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Interstitial lung diseases; Pulmonary arterial hypertension

Most Recent Events

29 Oct 2025 Phase-II clinical trials in Interstitial lung diseases in USA (PO) (NCT07175038)
29 Oct 2025 Phase-II clinical trials in Pulmonary arterial hypertension in USA (PO) (NCT07175038)
29 Sep 2025 AllRock Bio plans a phase IIa ROCSTAR trial for Pulmonary arterial hypertension and Interstitial lung disease in late 2025 (NCT07175038)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com